Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalbavancin plus rifampicin for prosthetic hip and knee joint infections
2020-003169-20Phase 2Active
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Jul 2020
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, single-arm trial of dalbavancin in osteomyelitis (OM), periprosthetic joint infection (PJI), Staphylococcus aureus infection and 1 more, sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Primary efficacy at 12 months. Started Jul 2020; status: active.
02
Drugs
dalbavancin
03
Conditions
osteomyelitis (OM)periprosthetic joint infection (PJI)Staphylococcus aureus infectionstreptococcal infection
Beyond the preview
Go deeper on 2020-003169-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003169-20.